Published in J Urol on June 01, 1999
Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol (2006) 1.83
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. J Urol (2007) 1.77
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol Res (2004) 0.88
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Prostate epithelial stem cells are resistant to apoptosis after α1-antagonist treatment. The impact for BPH patients. Cent European J Urol (2011) 0.86
Novel quinazoline-based compounds impair prostate tumorigenesis by targeting tumor vascularity. Cancer Res (2007) 0.85
Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia. World J Urol (2010) 0.83
Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists. Gene Ther Mol Biol (2008) 0.83
Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells. PLoS One (2014) 0.81
Hypothesis to explain poor outcomes in the ALLHAT and V-HeFT trials: decreased expression of heat shock proteins. Curr Control Trials Cardiovasc Med (2001) 0.80
Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One (2012) 0.80
An introduction to acinar pressures in BPH and prostate cancer. Nat Rev Urol (2013) 0.79
Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. J Korean Med Sci (2008) 0.79
Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder. Urology (2005) 0.78
Terazosin treatment induces caspase-3 expression in the rat ventral prostate. J Clin Med Res (2013) 0.76
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity. PLoS One (2016) 0.75
Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat. PLoS One (2015) 0.75
Medical treatment of benign prostatic hyperplasia. Postgrad Med J (2007) 0.75
The role of the prostatic stroma in chronic prostatitis/chronic pelvic pain syndrome. Inflamm Res (2009) 0.75
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation (1995) 5.06
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
Prostate specific antigen: a decade of discovery--what we have learned and where we are going. J Urol (1999) 3.19
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst (1998) 3.13
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol (2001) 2.83
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Consensus criteria for traumatic grief. A preliminary empirical test. Br J Psychiatry (1999) 2.75
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Prostate-specific antigen: what's new in 1997. Oncology (Williston Park) (1997) 2.06
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ (2008) 1.99
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Spread of prostatic cancer to bone. Urology (1983) 1.94
Seizures associated with antidepressants: a review. J Clin Psychiatry (1993) 1.91
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol (2002) 1.91
Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol (1994) 1.87
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology (1997) 1.79
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol (2000) 1.72
Caspase control: protagonists of cancer cell apoptosis. Exp Oncol (2012) 1.69
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
Efficient immortalization of luminal epithelial cells from human mammary gland by introduction of simian virus 40 large tumor antigen with a recombinant retrovirus. Proc Natl Acad Sci U S A (1991) 1.63
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst (1991) 1.57
Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum (1999) 1.56
OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology (1995) 1.56
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst (1993) 1.54
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res (1994) 1.53
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Bladder cancer and squamous metaplasia in spinal cord injury patients. J Urol (1977) 1.53
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol (1998) 1.50
Ablation of renal tumors in a rabbit model with interstitial saline-augmented radiofrequency energy: preliminary report of a new technology. Urology (1999) 1.49
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol (1997) 1.46
Impact of unfunded research in medicine, pathology, and surgery. South Med J (1995) 1.45
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ (2001) 1.43
Identification and characterization of circulating prostate carcinoma cells. Cancer (2000) 1.41
The use of bladder for total transplant ureteral reconstruction. J Urol (1998) 1.40
Comparison of robotic versus human laparoscopic camera control . J Urol (1995) 1.40
Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol (1996) 1.39
Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci (1998) 1.39
Influence of traumatic grief on suicidal ideation among young adults. Am J Psychiatry (1999) 1.38
The clinical implications of the prostate cancer prevention trial. BJU Int (2003) 1.38
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
The effect of hospital volume on cancer control after radical prostatectomy. J Urol (2005) 1.36
Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res (2001) 1.35
Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol (1998) 1.34
p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res (1993) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
Partial nephrectomy: technique, complications and pathological findings. J Urol (1995) 1.30
Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol (1996) 1.30
Perspectives on care at the close of life. Caring for bereaved patients: "all the doctors just suddenly go". JAMA (2001) 1.30
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology (1998) 1.29
Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene (1993) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
Quality of life impairments associated with diagnostic criteria for traumatic grief. Psychol Med (2000) 1.28
Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl (1993) 1.28
Decreased 3H-thymidine incorporation by human bladder epithelial cells following exposure to urine from interstitial cystitis patients. J Urol (1996) 1.27
Quinazoline-based alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-beta signalling and I kappa B alpha induction. Br J Cancer (2003) 1.25
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology (2001) 1.24
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24
Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res (2000) 1.23
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Heredity and prostate cancer: a study of World War II veteran twins. Prostate (1997) 1.22
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ (1998) 1.22